Farhan Ullah | Computer-Aided Drug Designing | Best Researcher Award

Published on by AI Data Scientist

Farhan Ullah | Computer-Aided Drug Designing | Best Researcher Award

Doctorate Student at Huazhong University of science and technology, China

Farhan Ullah is a dynamic and forward-thinking researcher specializing in computational biology and artificial intelligence applications in drug discovery. He is currently a doctoral student at the Huazhong University of Science and Technology (HUST), China, where he conducts advanced research in molecular docking, machine learning, and database development. With a strong foundation in biological sciences and hands-on research experience, Farhan has emerged as a promising figure in AI-integrated biomedical innovation. His contributions span both methodological development and practical application, particularly in molecular dynamics simulations and drug repurposing for major global diseases such as COVID-19, cancer, and diabetes.

Profile

Google Scholar

Education

Farhan completed his undergraduate and master’s degrees from Abdul Wali Khan University Mardan, where he laid the academic groundwork in biological sciences and computational tools. Demonstrating early research interest and technical capabilities, he secured a Research Associate position at S-Khan, gaining three years of valuable experience in real-world scientific analysis and collaboration. Currently, he is pursuing his Ph.D. in the School of Life Science and Technology at HUST. His doctoral studies focus on the integration of machine learning models into bioinformatics pipelines, aiming to bridge the gap between data-driven methodologies and biomedical applications.

Experience

Farhan Ullah’s experience spans academia and applied research. His early career as a Research Associate prepared him for advanced scientific inquiry and enabled him to participate in several impactful research projects. At HUST, he has taken part in over 20 completed and 4 ongoing research endeavors involving drug repurposing, virtual screening, molecular dynamics, and AI-guided compound discovery. He has authored over 20 peer-reviewed journal articles indexed in SCI and Scopus, reflecting a consistent record of scholarly contribution. His citation count has reached 81, and he is regularly referenced by fellow scientists and AI researchers in the life sciences.

Research Interest

Farhan’s primary research interest lies in machine learning-assisted drug discovery. His work utilizes AI algorithms and molecular dynamics simulations to repurpose existing drugs and develop new therapeutic agents against diseases such as COVID-19, cancer, and diabetes. He also specializes in constructing databases that serve as comprehensive repositories of phytochemicals, protein structures, and disease biomarkers. His research combines physics-based modeling with generative AI frameworks such as GANs and VAEs to improve molecular targeting and binding predictions. This unique combination of deep learning and biological data interpretation has made his work highly relevant to modern-day challenges in pharmaceutical development.

Award

Farhan’s research and academic excellence make him an excellent candidate for awards like the “Best Research Scholar Award” or “Excellence in Research.” His involvement in interdisciplinary, collaborative projects and high-impact publications in top journals reflects his innovation and commitment to solving global health problems using AI. His contribution to computational drug design and biological data integration has drawn attention from international academic circles, and his growing citation record substantiates his influence in the field. These accomplishments indicate his readiness for broader academic recognition.

Publication

Farhan has co-authored several significant research papers.

  1. A molecular dynamics simulations analysis of repurposing drugs for COVID-19 using bioinformatics methods, Journal of Biomolecular Structure and Dynamics, 2024 – Cited by 1 article.

  2. Identification of lead compound screened from the natural products atlas to treat renal inflammasomes using molecular docking and dynamics simulation, Journal of Biomolecular Structure and Dynamics, 2024 – Cited by 5 articles.

  3. A computational approach to fighting type 1 diabetes by targeting 2C Coxsackie B virus protein with flavonoids, PLoS ONE, 2023 – Cited by 5 articles.

  4. AVPCD: a plant-derived medicine database of antiviral phytochemicals for cancer, Covid-19, malaria and HIV, Database, 2023 – Cited by 7 articles.

  5. DBHR: a collection of databases relevant to human research, Future Science OA, 2022 – Cited by 10 articles.

  6. The Cancer Research Database (CRDB): Integrated Platform to Gain Statistical Insight Into the Correlation Between Cancer and COVID-19, JMIR Cancer, 2022 – Cited by 4 articles.

  7. An innovative user-friendly platform for Covid-19 pandemic databases and resources, Computer Methods and Programs in Biomedicine Update, 2021 – Cited by 16 articles.
    These publications not only highlight Farhan’s research capability but also his focus on real-world application and public health impact.

Conclusion

Farhan Ullah is an accomplished young researcher with a multidisciplinary focus that blends AI, molecular biology, and data science. His academic journey, from foundational studies in Pakistan to cutting-edge research in China, reflects his determination and excellence. With a strong portfolio of impactful publications and significant contributions to computational drug discovery and database development, Farhan continues to push the boundaries of AI applications in life sciences. He stands out as a scholar whose work has both theoretical depth and practical significance, making him a valuable asset to the global scientific community.

Yufeng Chen | R&D of New Drugs | Best Researcher Award

Published on by AI Data Scientist

Prof. Dr. Yufeng Chen | R&D of New Drugs | Best Researcher Award

Deputy Director at Department of Nuclear Medicine, General Hospital of Northern Theater Command, China

Prof. Yufeng Chen serves as the Deputy Director of the Department of Nuclear Medicine at the General Hospital of Northern Theater Command. With a career dedicated to neuropharmacology and nuclear imaging, Prof. Chen has developed a unique interdisciplinary expertise that bridges traditional pharmacological approaches with advanced medical imaging techniques. His work focuses on developing innovative drugs for the treatment of depression, memory disorders, and neuropathic pain, while also contributing to nuclear medicine through PET/MR imaging research. He is a recognized reviewer for several international journals, including Pharmacology, Biochemistry and Behavior, Pharmaceutical Biology, and Clinics. His scholarly output includes 15 SCI-indexed articles and 3 patents in pharmacology and nuclear imaging.

Profile

Scopus

Education

Prof. Chen completed his pharmacy education at the Second Military Medical University, earning both doctoral and post-doctoral credentials with a focus on metabolomics. This academic foundation equipped him with a comprehensive understanding of molecular biology, drug metabolism, and system-wide pharmacological effects. His doctoral research laid the groundwork for later investigations into plant-based therapeutics and neurochemical mechanisms. Throughout his education, Prof. Chen has demonstrated a consistent focus on developing practical solutions from fundamental scientific insights, especially in the realms of traditional medicine and neuropharmacology.

Experience

Prof. Chen has amassed years of research and clinical experience, blending pharmacological discovery with nuclear medicine applications. In his role as Deputy Director, he has spearheaded several clinical and laboratory initiatives that enhance diagnostic precision and therapeutic targeting using PET/MR technologies. Beyond his institutional responsibilities, he has collaborated extensively with interdisciplinary teams, contributing to both basic research and translational clinical projects. As an editorial reviewer and scientific advisor, he has engaged deeply with the academic community, ensuring research quality and guiding novel contributions in pharmacology.

Research Interest

Prof. Chen’s research primarily centers on the R&D of novel drugs targeting neurological and psychiatric conditions, especially those involving chronic and acute pain, memory dysfunction, and depression. In addition, he has made substantial contributions to the application of PET/MR imaging in localizing disease markers. His investigations into the Chinese traditional medicinal plant Paederia scandens revealed multiple compounds with potent antinociceptive effects, contributing to drug development from ethnopharmacological sources. His imaging research with 11C-Choline PET for localizing epileptogenic foci and the development of 18F-labeled AlF-FAPI PET tracers for assessing myocardial fibrosis are recognized as pioneering efforts.

Award

Prof. Chen is a strong contender for the Best Researcher Award due to his multidisciplinary innovation and impact. His work in elucidating mechanisms of action for traditional medicines and translating molecular discoveries into diagnostic imaging applications has garnered significant academic citations and institutional recognition. He has led or contributed to multiple grant-supported projects funded by the Natural Science Foundation of Liaoning Province and the Shenyang Municipal Natural Science Foundation. These efforts have reinforced his reputation as a research leader with both academic and practical influence.

Publication

Prof. Chen’s scientific contributions have been widely cited and respected in the academic community, with a total of 239 citations and an h-index of 9. Selected key publications include:

Chen Y, et al. (2025). “Simultaneous 18F-labeled AlF-FAPI PET/MR images…” Clinics (Sao Paulo), 80:100624 – cited by 12 articles.

Chen YF, et al. (2024). “Antinociceptive iridoid glycosides…” J Asian Nat Prod Res, 26(7):788-794 – cited by 10 articles.

Tong YN, Guo J, Chen YF, et al. (2022). “Antimicrobial limonoids…” J Asian Nat Prod Res, 24(3):238-244 – cited by 8 articles.

Chen YF, et al. (2020). “A new role of 11C-Choline PET…” CNS Neurosci Ther, 26(1):144-147 – cited by 20 articles.

Shi GB, et al., Chen YF* (2015). “Antinociceptive activity of astragaloside IV…” Behav Pharmacol, 26(5):436-46 – cited by 18 articles.

Shi GB, et al., Chen YF* (2014). “Evaluation of wound-healing…” Pak J Pharm Sci, 27(1):91-5 – cited by 16 articles.

Chen YF, et al. (2014). “Mechanism involved in antinociceptive activity…” CNS Neurosci Ther, 20(2):188-90 – cited by 14 articles.
These articles reflect the breadth of Prof. Chen’s research, ranging from phytochemical analyses to the application of nuclear imaging in clinical neurology.

Conclusion

Prof. Yufeng Chen is a distinguished researcher whose interdisciplinary contributions have bridged neuropharmacology and nuclear medicine. His work not only deepens scientific understanding of traditional therapeutic compounds but also enhances modern diagnostic methods through PET/MR innovations. With impactful publications, ongoing research projects, patents, and clinical translation of discoveries, Prof. Chen exemplifies excellence in research and innovation. His leadership in both academic and clinical settings, combined with his pioneering investigations, make him a deserving nominee for the Best Researcher Award.